Information Provided By: 
Fly News Breaks for December 10, 2018
BTX
Dec 10, 2018 | 17:22 EDT
Oppenheimer analyst Kevin DeGeeter started BioTime with an Outperform rating and $3.50 price target. New management is transforming BioTime from a holding company of multiple technology platforms to a product development company "committed to allocating necessary resources to the most promising drug," OpRegen for the treatment of dry age-related macular degeneration, DeGeeter tells investors in a research note. He expects OpRegen to have peak end-market revenue of $1.3B.
News For BTX From the Last 2 Days
There are no results for your query BTX
